Pacylex will present three posters at two upcoming medical conferences, and participate in the Annual BIO Meeting
EDMONTON, ALBERTA, CANADA / ACCESSWIRE / May 27, 2020 / PACYLEX PHARMACEUTICALS, INC. a pre-IND-stage pharmaceutical company targeting cancers with a new first-in-class therapeutic, announced today that its chief executive officer, Michael Weickert, will participate in the BIO 2020 conference being held virtually June 8-12, 2020. The company’s chief medical officer, John Mackey MD will present a poster describing the Phase 1 program set to launch later this year at the ASCO 2020 conference being held virtually May 29-31, 2020. Additionally, Dr. Mackey and the company’s chief science officer and principal founder, Luc Berthiaume, Ph.D., will present posters describing the therapeutic potential in breast cancer and lymphoma respectively at the AACR 2020 conference being held virtually June 22-24, 2020.
To view the full announcement, including visuals, bios, downloadable resources, and more, click here.
- Pacylex had an abstract accepted for presentation as a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting 2020.
- Pacylex also had two abstracts accepted for presentation as posters at the American Association for Cancer Research (AACR) Annual Meeting 2020.
- Pacylex will participate in The Biotechnology Innovation Organization (BIO) 2020 International Convention scheduled for June 8-12 2020.